A comprehensive view of Takeda Pharmaceutical Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Beauty & Personal Care Market Intelligence Service.
FDA approves subcutaneous administration of Takeda’s ENTYVIO (vedolizumab) for maintenance therapy in moderately to severely active Crohn’s Disease
Published:
April 19, 2024
by Business Wire
|
Leaders from Genentech, Bayer, Novo Nordisk, Takeda and others to be keynote speakers at Veeva Commercial Summit; speakers to discuss strategies for effective commercialization and customer engagement
Published:
April 17, 2024
by PR Newswire
|
Takeda is closing production at its gene therapy plant in Orth, Austria, resulting in nearly 200 job losses; despite attempts to sell the adeno-associated virus gene therapy facility, the Japan-based firm was unable to find a buyer
Published:
March 13, 2024
by FiercePharma
|
Takeda's HYQVIA approved by FDA as maintenance therapy for adult chronic inflammatory demyelinating polyneuropathy patient; the therapy can be infused up to once per month and can be administered by healthcare professionals or self-administered
Published:
January 23, 2024
by Contify Life Science News
|
Takeda selects Biologics by McKesson as specialty pharmacy provider for FDA-approved oral targeted therapy Fruzaqla for adults with metastatic colorectal cancer; the treatment is the first targeted therapy for the condition in over a decade
Published:
November 15, 2023
by McKesson Corp.
|
Ask us about our Beauty & Personal Care market view